Cytosorbents Corporation is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Princeton, NJ. Its latest filed balance sheet (2025-12-31) shows total assets of $41 million (its filed statements).
Product businessSurgical & Medical Instruments & ApparatusPrinceton, NJfilings since 20048 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.2 out of ten, 8 of 9 metrics filed and 1 estimated: past 2.8 out of ten, present 5.0 out of ten, future 4.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.9 out of ten. 6 warning events since 2017; the latest 2026-07-06. 9th percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.9 out of ten. +18.2% a year over 10 filed years; profitable in 0 of 10. 39th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.3 out of ten. CrossAssetData estimate 3.3/10, confidence 35 of 100 (one part). 33rd percentile among 119 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.0 out of ten. ROE -139%: lost 139¢ per shareholder dollar. Leverage 87%: owes 87¢ per asset dollar. 40th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.6 out of ten. bottom 36% of 109 in its family; net margin -22.1%. 36th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 9.2 out of ten. top 9% of 90 in its family for leadership; chief executive since 2009. 91st percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 4.0 out of ten. bottom 40% of 104 in its family for room to expand. 40th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 3.4 out of ten. bottom 33% of 105 in its family for growth drivers. 33rd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 7.5 out of ten. top 25% of 88 in its family for expectations against reality. 75th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-30 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 8-K, 2026-09-23. Filings on record since 2004. Read from EDGAR 2026-10-12.
Who runs it
Chan, Phillip P. (Chief Executive Officer); Capponi, Vincent (President and COO); Mariani, Peter J (Chief Financial Officer); Deliargyris, Efthymios (Chief Medical Officer); Sobel, Alan D. (director); Bator, Michael G. (director); Jones, Edward Raymond (director); Kim, Jiny (director). 8 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.